Home > Healthcare > Medical Services > Inpatient and Outpatient Services > Bile Duct Cancer Market

Bile Duct Cancer Market Size

  • Report ID: GMI8578
  • Published Date: Mar 2024
  • Report Format: PDF

Bile Duct Cancer Market Size

Bile Duct Cancer Market size was valued at USD 3.6 billion in 2023 and is expected to expand at a CAGR of 8.5% between 2024 and 2032. One of the major growth drivers is the increasing incidence of bile duct cancer globally, which has led to a greater demand for effective treatment options. Additionally, advancements in medical technology and increased awareness among healthcare professionals and patients have contributed to the market's growth.

 

Furthermore, the rise in research and development activities focusing on innovative therapies and targeted treatments for bile duct cancer has propelled market expansion. For instance, in 2021, the U.S. FDA granted accelerated approval to the targeted therapeutic infigratinib (Truseltiq) for certain adults with previously treated advanced cholangiocarcinoma. Thus, with ongoing efforts to improve early detection and development of more personalized treatment approaches.
 

Bile duct cancer, also known as cholangiocarcinoma, is a rare but aggressive type of cancer that forms in the bile ducts, which are thin tubes that connect the liver and the gallbladder to the small intestine. Bile duct cancer can occur in any part of the bile duct system, including the intrahepatic (inside the liver) and extrahepatic (outside the liver) bile ducts.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of bile duct cancer reached USD 3.6 billion in 2023 and is set to cross USD 7.4 billion by 2032, owing to the increasing incidence of bile duct cancer globally, the greater demand for effective treatment options, and advancements in medical technology.

The surgery segment held a dominant market share of 36.3% in 2023, owing to the advent of advanced surgical techniques such as minimally invasive approaches that enable more precise and effective procedures.

North America held a market share of 37.8% in 2023 and is expected to reach USD 2.7 billion by 2032, favored by a well-established healthcare infrastructure, high adoption of advanced medical technologies, and increased awareness about early diagnosis & treatment options.

AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Fresenius SE & Co. KGaA, Genentech, Inc., GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Pfizer Inc., and QED Therapeutics.

Bile Duct Cancer Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 188
  • Countries covered: 19
  • Pages: 115
 Download Free Sample